


## Indomethacin

Cat. No.:	HY-14397
CAS No.:	53-86-1
Molecular Formula:	C <sub>19</sub> H <sub>16</sub> ClNO <sub>4</sub>
Molecular Weight:	357.79
Target:	COX; Autophagy
Pathway:	Immunology/Inflammation; Autophagy
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (279.49 mM; Need ultrasonic)  
Ethanol : 12.5 mg/mL (34.94 mM; Need ultrasonic)  
H<sub>2</sub>O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.7949 mL	13.9747 mL	27.9494 mL
	5 mM	0.5590 mL	2.7949 mL	5.5899 mL
	10 mM	0.2795 mL	1.3975 mL	2.7949 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% corn oil  
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

### BIOLOGICAL ACTIVITY

<b>Description</b>	Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC <sub>50</sub> s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells <sup>[1]</sup> . Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes <sup>[2]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	Human COX-1 18 nM (IC <sub>50</sub> , in CHO cells)	Human COX-2 26 nM (IC <sub>50</sub> , in CHO cells)
<b>In Vitro</b>	Indomethacin is a potent and nonselective inhibitor of COX1 and COX2, with IC <sub>50</sub> s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin inhibits lipopolysaccharide (LPS)-induced PGE2 production (COX-2) in a human whole blood assay with a potency (IC <sub>50</sub> =0.68±0.17 μM), and suppresses coagulation-induced TXB2 production (COX-1) (IC <sub>50</sub> =0.19±0.02 μM). Indomethacin blocks COX-1 with an IC <sub>50</sub> of 20±1 nM in U937 cell microsomes at a low arachidonic acid concentration (0.1 μM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Indomethacin dose-dependently inhibits both the carrageenan-induced rat paw oedema (ED <sub>50</sub> , 2.0 mg/kg), hyperalgesia (ED <sub>50</sub> , 1.5 mg/kg), and is also effective at reversing LPS-induced pyrexia in rats (ED <sub>50</sub> , 1.1 mg/kg) <sup>[1]</sup> . Indomethacin (2.5 mg/kg, i.p) decreases the number of NeuN <sup>+</sup> cells in the animals at 8 days after ET-1 injection. Indomethacin also reduces microglia/macrophage activation at 14 days. Indomethacin significantly increases the number of SVZ DCX <sup>+</sup> cells/field at 14 days post stroke <sup>[3]</sup> . Indomethacin (22.9 mg/kg, p.o.) produces 8 to 10 linear mucosal lesions extended from the fundic to pyloric area of stomach wall <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## PROTOCOL

### Animal Administration <sup>[3]</sup>

Rats<sup>[3]</sup>

To investigate the effects of Indomethacin treatment on both microglia activation, neuroprotection and adult neurogenesis, rats are divided in four experimental groups: animals injected with ET-1, treated with sterile saline (i.p.) for 7 days and perfused at 8 days following ET-1 injection (group 1, n=4); animals injected with ET-1, treated with Indomethacin (2.5 mg/kg, i.p) for 7 days and perfused at 8 days following ET-1 injection (group 2, n=4); animals injected with ET-1, treated with sterile saline (i.p.) for 7 days and perfused at 14 days following ET-1 injection (group 3, n=4); animals injected with ET-1, treated with Indomethacin (2.5 mg/kg, i.p) for 7 days and perfused at 14 days following ET-1 injection (group 4, n=4). After survival times of 7 or 14 days, animals are deeply anesthetized with a mixture of ketamine hydrochloride (72 mg/kg, i.p.) and xylazine hydrochloride (9 mg/kg, i.p.). After the verification of complete absence of both the corneal and the paw withdraw reflexes, the animals are transcardially perfused with heparinized 0.9% warm phosphate-buffered saline (PBS) followed by 4% cold paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4. Brains are post-fixed for 24 h in the same fixative and cryoprotected in different gradients of sucrose-glycerol solutions over 7 days. The tissue is then frozen in an embedding medium, and cut at 30 μM in the coronal plane using a cryostat. Sections are then mounted onto gelatinized slides and stored in a freezer at -20°C<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Chem Mater. 2017, 29(19):8221-8238.
- Clin Transl Med. 2021 Oct;11(10):e548.
- J Med Chem. 2021 Feb 23.
- Eur J Med Chem. 8 August 2021, 113743.
- Int J Nanomedicine. 2020 May 1;15:3087-3098.

---

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. *Br J Pharmacol.* 1997 May;121(1):105-17.
- [2]. Lopes RS, et al. Indomethacin treatment reduces microglia activation and increases numbers of neuroblasts in the subventricular zone and ischaemic striatum after focal ischaemia. *J Biosci.* 2016 Sep;41(3):381-94.
- [3]. Afroz S, et al. Concentrated phosphatidic acid in cereal brans as potential protective agents against indomethacin-induced stomach ulcer. *J Agric Food Chem.* 2016 Aug 26.
- [4]. Jorge Vallecillo-Hernández, et al. Indomethacin Disrupts Autophagic Flux by Inducing Lysosomal Dysfunction in Gastric Cancer Cells and Increases Their Sensitivity to Cytotoxic Drugs. *Sci Rep.* 2018 Feb 26;8(1):3593.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA